RA CAPITAL MANAGEMENT, L.P. → Sana Biotechnology, Inc. (SANA)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

82 filings by this filer

81 other filings in the data moat

Short Interest · settle 2026-07-31

DTC 16.33

42,148,007 shares short · +6.1% vs prior

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Filed	Form	Issuer	Stake	Shares
2026-08-17	SCHEDULE 13G	Latigo Biotherapeutics, Inc.	—	—	view →
2026-08-14	SCHEDULE 13D/A	SEPTERNA, INC.	—	5,525,324	view →
2026-08-11	SCHEDULE 13D/A	Wave Life Sciences, Inc.	—	34,314,406	view →
2026-08-10	SCHEDULE 13D/A	SAB Biotherapeutics, Inc.	—	9,609,852	view →
2026-07-23	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC.	—	18,415,956	view →
2026-07-22	SCHEDULE 13D/A	Freenome, Inc.	—	15,367,270	view →
2026-07-21	SCHEDULE 13D/A	VOR BIOPHARMA INC.	—	12,937,855	view →
2026-07-20	SCHEDULE 13G	Agenus Inc.	—	—	view →
2026-07-07	SCHEDULE 13D/A	Climb Bio, Inc. CLYM	33.00%	23,249,186	view →
2026-07-02	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	4.10%	1,985,541	view →
2026-06-26	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	6.00%	2,915,742	view →
2026-06-24	SCHEDULE 13D/A	SOLID BIOSCIENCES INC. SLDB	—	12,036,126	view →
2026-06-22	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	3,654,307	view →
2026-06-18	SCHEDULE 13D	Parabilis Medicines, Inc. PBLS	23.80%	28,933,371	view →
2026-06-15	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	5,138,703	view →
2026-06-15	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC. ARTV	36.60%	17,811,623	view →
2026-06-03	SCHEDULE 13G	Editas Medicine, Inc. EDIT	—	—	view →
2026-05-14	SCHEDULE 13D/A	WEREWOLF THERAPEUTICS, INC. HOWL	—	6,116,140	view →
2026-05-13	SCHEDULE 13D/A	ARTIVA BIOTHERAPEUTICS, INC. ARTV	—	16,377,468	view →
2026-01-09	SCHEDULE	Cidara Therapeutics, Inc.	—	—	view →

Showing 20 of 81

RA CAPITAL MANAGEMENT, L.P. → Sana Biotechnology, Inc. SANA

Item 4 — Purpose of Transaction

Cross-References

Other Filings by RA CAPITAL MANAGEMENT, L.P.

Want this depth on every filing the moment it hits SEC EDGAR?